Tag: pharmaceuticals
-
Engineered Protein Advances to Treat Genetic Blood Disorders
4 May 2016. Lab tests by a biotechnology company show an engineered protein can block the actions of genes responsible for low normal hemoglobin production in people with inherited blood disorders like sickle cell disease. The findings of researchers from Acetylon Pharmaceuticals Inc. in Boston were reported in April in the journal PLoS One. Acetylon…
-
Patent Granted for RNA Transcription Technology
3 May 2016. A technology that blocks RNA molecules from activating chemicals in the body suppressing the working of genes to treat or prevent disease received a U.S. patent. The Patent and Trademark Office awarded patent number 9,328,346 to five inventors and assigned the patent to the parent company of Massachusetts General Hospital in Boston.…
-
Drug Pricing Reform Even Big Pharma Might Like
2 May 2016. At a press event in Washington, D.C. last week, Representative Lloyd Doggett of Texas, a champion of lower prescription drug prices, took aim at drug companies and their business practices. “An unaffordable drug is 100 percent ineffective,” Doggett told an audience at Center for American Progress on 26 April. He noted that…
-
Challenge Seeks New Regenerative Tools with Stem Cells
29 April 2016. A challenge offered through InnoCentive is seeking new methods of harnessing adult stem cells for regenerative medicine. The competition has a total purse of $15,000 and a 24 June 2016 deadline for submissions. The sponsor of the challenge, pharmaceutical company Boehringer Ingelheim, also seeks research plans related to the challenge proposals, with…
-
Engineered T-Cells Get High Leukemia Remission in Trial
28 April 2016. A clinical trial shows engineered immune-system cells transplanted in patients with one form of leukemia achieves a 93 percent remission rate. Results of the trial, at the Fred Hutchinson Cancer Research Center in Seattle, were reported in the 25 April issue of The Journal of Clinical Investigation. Fred Hutchinson Center researchers were…
-
Sanofi Adopting Big Data for Diabetes Drug Adherence
27 April 2016. Drug maker Sanofi is partnering with two research institutes to harness big data analytics for predicting how people with type 2 diabetes will take their medications. Sanofi’s U.S. division in Bridgewater, New Jersey announced the collaborations today with Duke Clinical Research Institute in Durham, North Carolina and Center for Assessment Technology and…
-
NeuroVive, Penn Partner on Traumatic Brain Injury
26 April 2016. A pharmaceutical company in Sweden is collaborating with University of Pennsylvania’s medical school in preclinical studies of a new drug that protects against long term damage caused by traumatic brain injury. Financial terms of the agreement between NeuroVive Pharmaceutical AB in Lund, Sweden and the university were not disclosed. NeuroVive develops drugs…
-
Trials to Test New Treatments for Inherited Alzheimer’s
25 April 2016. Clinical trials are planned to assess experimental treatments and new diagnostics for inherited forms of Alzheimer’s disease. The new studies, which extend earlier trials of drugs to treat inherited Alzheimer’s disease, are funded by a $4.3 million grant from Alzheimer’s Association in Chicago. Like the earlier trials, the new round of studies…
-
NIH Closes Two Clinical Facilities for Sterility Issues
20 April 2016. National Institutes of Health closed two of its clinical facilities found not in compliance with safety and quality standards that could put patients at risk. Facilities at NIH closed for not meeting Current Good Manufacturing Practice standards are a cell therapy production lab at National Cancer Institute and a production center for…
-
Nanoparticles Designed for Asthma, Allergy Treatments
19 April 2016. A technique for masking allergy or asthma treatments in biodegradable nanoparticles is shown in lab mice to quickly build a tolerance in the immune system for offending allergens. A medical and engineering team at Northwestern University in Chicago published its findings yesterday, 18 April, in Proceedings of the National Academy of Sciences…